AltPep Corporation Presents New Preclinical Data at AAIC 2025 Demonstrating SOBIN-AD, its Custom-Designed Peptide for Alzheimer’s Disease, Increases Clearance of Aβ Toxic Oligomers and Inhibits Plaque Formation
AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases will today present new preclinical data at the Alzheimer’s Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada, reinforcing the promising potential of its lead compound, SOBIN-AD (Soluble Oligomer Binding INhibitor), as a treatment for early Alzheimer’s disease (AD).
AltPep Corporation Appoints Alan Colowick, M.D., M.P.H. to Board of Directors
AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced the appointment of Alan Colowick, M.D., M.P.H., of Matrix Capital Management Company to its Board of Directors.
AltPep Corporation Welcomes Denis Sirringhaus as Vice President of Business Development
AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that Denis Sirringhaus has joined the company as Vice President of Business Development.
AltPep Study Published in Nature Journal, Scientific Reports, Further Affirms Potential of Blood Test to Detect Alzheimer's Disease
AltPep Corporation (“AltPep” or the “Company”), a privately held biotechnology company dedicated to early disease-modifying treatments and detection tools for amyloid diseases, today announced that the peer-reviewed Nature journal Scientific Reports has published new results from the Company’s evaluation of its novel SOBA-AD blood test, aimed at detecting Alzheimer’s disease (AD).
AltPep Appoints Soon Hyouk Lee to Newly Created Position of Chief Business Officer
AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that Soon Hyouk Lee has assumed the position of Chief Business Officer of AltPep. In this role, Soon will lead AltPep’s corporate and business development.
AltPep Further Strengthens Advisory Board with Appointment of Steven E. Kahn, M.B., Ch.B.
AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced the appointment of Steven E. Kahn, M.B., Ch.B. to its Advisory Board. The Advisory Board consists of world-renowned experts in discovery, preclinical and clinical research in Alzheimer’s disease, other neurodegenerative disorders and now diabetes.
AltPep Corporation Announces Close of $53 Million Series B Financing to Advance Its Novel Therapeutics for both Alzheimer’s and Parkinson’s Diseases into the Clinic
AltPep Corporation, a privately-held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced the completion of a $52.9 million Series B financing round. The financing was led by Senator Investment Group, LP, with participation from new financial investors, Section 32, Korea-based Partners Investment, and Eli Lilly and Company. Investors in AltPep’s Series A, including Alexandria Venture Investments and Matrix Capital Management Company, LP, also participated in the Series B. Proceeds from the round will primarily be used to accelerate AltPep’s SOBIN™ therapeutics into Phase 1 clinical trials for both Alzheimer’s and Parkinson’s diseases. Funds will also be used to advance AltPep’s first SOBA™ diagnostic, which has FDA Breakthrough Designation, toward FDA clearance. In conjunction with the financing, Rohit Vanjani of Senator Investment Group will be appointed to AltPep’s Board of Directors and Ronald DeMattos, Ph.D., Senior Vice President and Chief Scientific Officer for Neurobiologicals at Lilly, will join AltPep’s Scientific Advisory Board.
AltPep Strengthens Advisory Board with Three Leading Experts in Alzheimer’s Disease and Neurodegenerative Disorders
AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced the appointment of three new Advisory Board members: Paul Aisen, M.D., Sam Gandy, M.D., Ph.D., and Charlie Glabe, Ph.D. The advisory board now consists of world-renowned experts in discovery, preclinical and clinical research in Alzheimer’s disease and other neurodegenerative disorders.
A New Study in the Proceedings of the National Academy of Sciences (PNAS) Demonstrates the Ability of a Novel Peptide to Selectively Detect and Neutralize an Early Molecular Trigger of Alzheimer’s and Other Neurodegenerative Diseases
AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that this week the Proceedings of the National Academy of Sciences (PNAS) will publish results of a groundbreaking study demonstrating a customized, synthetic peptide’s ability to selectively detect Alzheimer’s disease. The novel approach detailed in "SOBA: Development and Testing of a Soluble Oligomer Binding Assay for Detection of Amyloidogenic Toxic Oligomers" allows detection of Alzheimer’s disease at all stages, including presymptomatic cases, as well as differentiation from different amyloid-related neurodegenerative diseases. The technology was developed in the Daggett lab at the University of Washington, and AltPep is a spinout developing a revolutionary platform based on this technology focusing on early detection and treatments, with the aim to change the course of amyloid diseases.
AltPep Appoints Nancy Hill to Newly Created Position of Chief Product Officer
AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that accomplished executive Nancy Hill has assumed the newly created role of Chief Product Officer. In this role, Nancy is responsible for product development and commercialization of AltPep’s pipeline.
